General MedicationsNASALGeneric
DIAPID
LYPRESSIN
Standard Dose
0.185MG/ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary
Approval overview DIAPID is listed in Drugs@FDA under application 016755 (NDA).
Marketing status: Discontinued Active ingredient LYPRESSIN Form and strength SOLUTION;NASAL - 0.185MG/ML Sponsor NOVARTIS Submission history See approval history documents.
Structured Monograph
Clinical summary
Approval overview DIAPID is listed in Drugs@FDA under application 016755 (NDA). Marketing status: Discontinued Active ingredient LYPRESSIN Form and strength SOLUTION;NASAL - 0.185MG/ML Sponsor NOVARTIS Submission history See approval history documents.
Monitoring
- • Marketing status: Discontinued
Interaction Notes
- No interaction notes stored yet.